NCT04070495View on ClinicalTrials.gov

A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions
Parkinson's Disease
Interventions
DRUG

KW-6356

A single oral dose will be administered at Day 1 and 15

DRUG

Clarithromycin

400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28

DRUG

Rifampicin

600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21

Trial Locations (1)

Unknown

Medical Co. LTA Sumida Hospital, Sumida-ku

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04070495 - A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin | Biotech Hunter | Biotech Hunter